Post Offer Free
Wuhan Yuancheng Gongchuang Technology Co,ltd
Wuhan Yuancheng Gongchuang Technology Co,ltd

China Pharmaceutical Raw Olaparib 763113-22-0 for Cancer Treatment AZD2281 manufacturer

2nd

Gold Index: 167643

You are here: home  > Pharmaceutical raw material  > Other pharmaceuticals  > Pharmaceutical Raw Olaparib 763113-22-0 for Cancer Treatment AZD2281

Pharmaceutical Raw Olaparib 763113-22-0 for Cancer Treatment AZD2281 

Price: 90.0 USD 
Payment Terms: T/T,D/A,WU,Money Gram;Bitcoin 
Place of Origin: Hubei, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Model No.: C24H23FN4O3
Production Capacity: 500kg//month
Delivery Date: 4-15days
CAS No.: 763113-22-0
Alias: Olaparib
usage: Olaparib
price: AZD-2281 price
effects: AZD-2281
Appearance: AZD-2281 powder
Means of Transport: Ocean,Air;Express
Packing: disguise package or as requ...
Brand Name: gongchuang
Purity: 99%
source: Olaparib from China
supplier: Olaparib supplier
Usage: AZD-2281 for medical
purity: 99% AZD-2281
Standard: USP/BP/USP Olaparib

Olaparib powder;Olaparib price; Olaparib source; Olaparib supplier;Olaparib anti-cancer; buy Olaparib;
Olaparib (AZD-2281) for sale; Azd2281 Olaparib

Olaparib

99% Raw Power Olaparib (AZD-2281) CAS 763113-22-0 Olaparib (AZD-2281)

Azd2281 Potent Parp1 / Parp2 Inhibitor Olaparib CAS 763113-22-0

Pharmaceutical Raw Power Olaparib CAS 763113-22-0 for Cancer Treatment


Olaparib is a kind of novel poly ADP-ribose polymerase (PARP) inhibitors, including PARP1, PARP2, and PARP3. PARP mediates a DNA-repair mechanism which plays a important role in DNA damage repair and apoptosis, so olaparib specifically targets on the DNA repair mechanism of the targeting cell DNA repair and take effects by attacking the critical vulnerabilities of cancer cells carrying mutations in BRCA1 and BRCA2. Owing to this mechanism, it can be used for the maintenance therapy of patients of severe recurrent ovarian cancer who has breast cancer susceptibility gene (BRCA) mutation as well as being sensitive to platinum drug. 

Product Description

Product Description  

laparib (AZD2281, Ku-0059436)

AZD2281 Ku-0059436

Olaparib (AZD2281, Ku-0059436) is a selective PARP1 / 2 inhibitor with an IC50 of 5 nM / 1 nM in cell-free assays, 300-fold stronger than that of Tankyrase-1. Phase 3

Chemical Name : 4-(3-(1-(cyclopropanecarbonyl)piperazine-4-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one

Olaparib CAS :763113-22-0

Olaparib MF:    C24H23FN4O3

Olaparib MW:    434.46

Olaparib Solubility (25°C) : DMSO 86 mg/mL warming (197.94 mM) Water 0.002 mg/mL (0.0 mM) Ethanol <1 mg/mL

Olaparib Stability :-20ºC Powder , 3 years : -80ºC Soluble in solvents 2years

Olaparib Usage:Olaparib is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Olaparib has been shown to induce significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Recent studies show that Olaparib increases radiosensitivity of a lung tumor xenograft, making it a potential candidate for use in combination with radiotherapy.


Olaparib Application

Ovarian cancer forms in the ovary, one of a pair of female reproductive glands where ova, or eggs, are formed.

Lynparza is a poly ADP-ribose polymerase (PARP) inhibitor that blocks enzymes involved in repairing damaged DNA. It is intended for women with heavily pretreated ovarian cancer that is associated with defective BRCA genes.

"Today's approval constitutes the first of a new class of drug for treating ovarian cancer," said Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research. "Lynparza is approved for patients with specific abnormalities in the BRCA gene and is an example of how a greater understanding of the underlying mechanisms of disease can lead to targeted, more personalized treatment.


Olaparib Description:

Olapanil is a novel poly-ADP ribose polymerase (PARP) inhibitor, including PARP1, PARP2, and PARP3. PARP mediates a mechanism of DNA repair and plays an important role in DNA damage repair and cell apoptosis. Therefore, the mechanism of DNA damage repair by targeting to cells is mediated by PARP1 and PARCA2 mutant cancer cells Of the critical loopholes in the role, can be used for breast cancer susceptibility gene (BRCA) mutations, platinum-sensitive drug-resistant patients with recurrent severe ovarian cancer maintenance therapy.

 

ABT-888 
GSK2126458 
VX950  
AZD2281  
AZD92911421373-65-0
E7080417716-92-8
Afatinib diMaleate439081-18-2
XL184 S-MALATE1140909-48-3
Crizotinib877399-52-5
Axitinib319460-85-0
WZ40021213269-23-8
Vandetanib443913-73-3
Sunitinib557795-19-4
Regorafenib755037-03-7
Imatinib152459-95-5
BMS777607 
BMS5121458  
Telatinib (BAY 57-9352)    
gsk1904529A  
LY2157299  
DMXAA(AS1404,ASA404) 
Brivanib(bms-540215)  
Brivanib alaninate(BMS-582664) 


Ms. Gina
skype Ms. Gina
Manager
Tel: 86-27-88211875
Mobile: 188 7222 0799
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on Hisupplier.com

Other products from this supplier

Company Info

Wuhan Yuancheng Gongchuang Technology Co,ltd [China (Mainland)]


Business Type:Manufacturer, Trading Company
City: Wuhan
Province/State: Hubei
Country/Region: China (Mainland)

Follow Us: Follow us on facebook Follow us on linkedin Follow us on Twitter

Gina:   skype
Service:   skype

You May Like: